GRTX
Galera Therapeutics, Inc.
$0.0980
+3.16%
No data for this timeframe.
Vol
SEC Reports7
Press Releases1
Recent Activity
May 22, 2026
SEC
Galera Therapeutics filed a Rule 425 communication reposting Obsidian Therapeutics' LinkedIn announcement of positive Ph
425 — Impact 7/10
May 19, 2026
SEC
Galera Therapeutics converted its remaining 42,839.11 shares of Series B Non-Voting Convertible Preferred Stock into 42,
8-K — Impact 8/10
May 15, 2026
Insider
Emerald Bioventures, LLC sold 20,813,818 shares
10%+ Owner @ $0.00 ($0.00)
May 15, 2026
Insider
Emerald Bioventures, LLC sold 20,813.819 shares
10%+ Owner @ $0.00 ($0.00)
May 13, 2026
earnings_calendar
GRTX Q1 2026 Earnings Scheduled — 2026-05-13
Apr 22, 2026
SEC
Galera Therapeutics is being acquired by Obsidian Therapeutics in a merger that will create a public company trading as
425 — Impact 7/10
Apr 14, 2026
Press
Galera Therapeutics (GRTX) is merging with private biotech Obsidian Therapeutics in an all-stock transaction, with the c
Impact 7/10
Apr 7, 2026
Insider
CHANG NANCY T sold 1,180,611 shares
Director @ $0.00 ($0.00)
Analyst Ratings
0Strong Buy
0Buy
4Hold
1Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 29, 2023 | Citigroup | MAINTAIN | Neutral → Neutral |
| Aug 16, 2023 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| Aug 10, 2023 | Piper Sandler | DOWNGRADE | Overweight → Neutral |
| Jul 17, 2023 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 22, 2023 | HC Wainwright & Co. | MAINTAIN | Buy |
Latest Reports
BULLISH
425
7/10
Galera Therapeutics filed a Rule 425 communication reposting Obsidian Therapeutics' LinkedIn announcement of positive Ph
May 22, 2026
BEARISH
8-K
8/10
Galera Therapeutics converted its remaining 42,839.11 shares of Series B Non-Voting Convertible Preferred Stock into 42,
May 19, 2026
BEARISH
Press
7/10
Galera Therapeutics (GRTX) is merging with private biotech Obsidian Therapeutics in an all-stock transaction, with the c
Apr 14, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 15, 2026 | Emerald Bioventures, | C | $0.00 |
| May 15, 2026 | Emerald Bioventures, | C | $0.00 |
| Apr 7, 2026 | CHANG NANCY | C | $0.00 |
| Apr 7, 2026 | CHANG NANCY | C | $0.00 |
| Apr 7, 2026 | FRIEDMAN MICHAEL | C | $0.00 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
3 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 15, 2026 | Emerald Bioventures, LLC | 10%+ Owner | C | 20,813,818 | $0.00 | $0.00 |
| May 15, 2026 | Emerald Bioventures, LLC | 10%+ Owner | C | 20,813.819 | $0.00 | $0.00 |
| Apr 7, 2026 | CHANG NANCY T | Director | C | 1,180,611 | $0.00 | $0.00 |
| Apr 7, 2026 | CHANG NANCY T | Director | C | 1,180.611 | $0.00 | $0.00 |
| Apr 7, 2026 | FRIEDMAN MICHAEL R. | Director | C | 5,336,870 | $0.00 | $0.00 |
| Apr 7, 2026 | FRIEDMAN MICHAEL R. | Director | C | 5,336.87 | $0.00 | $0.00 |
7 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 1 mixed, 3 neutral. Avg impact: 5.9/10.
BULLISH
425
7/10
Galera Therapeutics filed a Rule 425 communication reposting Obsidian Therapeutics' LinkedIn announc
May 22, 2026
BEARISH
8-K
8/10
Galera Therapeutics converted its remaining 42,839.11 shares of Series B Non-Voting Convertible Pref
May 19, 2026
BULLISH
425
7/10
Galera Therapeutics is being acquired by Obsidian Therapeutics in a merger that will create a public
Apr 22, 2026
NEUTRAL
425
5/10
Galera Therapeutics is being acquired by Obsidian Therapeutics in a merger, with a concurrent $350 m
Apr 22, 2026
NEUTRAL
425
6/10
Galera Therapeutics is being acquired by Obsidian Therapeutics in a merger transaction, with a $350
Apr 14, 2026
MIXED
8-K
6/10
Galera Therapeutics is being acquired by Obsidian Therapeutics in a merger transaction, with a concu
Apr 14, 2026
NEUTRAL
8-K
2/10
Galera Therapeutics has scheduled its Combined 2025 and 2026 Annual Meeting of Stockholders for May
Apr 3, 2026
Historical analyst distribution (last covering-analyst action Aug 2023): 0% buy across 7 analysts — 0 strong buy, 0 buy, 4 hold, 1 sell, 2 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2024-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2023-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
6 analyst firms have rated this stock: 4 upgrades, 5 downgrades, 6 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 29, 2023 | Citigroup | MAINTAIN | Neutral | Neutral |
| Aug 16, 2023 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Aug 10, 2023 | Piper Sandler | DOWNGRADE | Overweight | Neutral |
| Jul 17, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 22, 2023 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Feb 21, 2023 | Piper Sandler | INITIATE | — | Overweight |
| Feb 16, 2023 | B of A Securities | UPGRADE | Underperform | Buy |
| Feb 16, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| May 27, 2022 | B of A Securities | DOWNGRADE | Neutral | Underperform |
| Dec 20, 2021 | Citigroup | MAINTAIN | — | Buy |
| Dec 15, 2021 | HC Wainwright & Co. | UPGRADE | Neutral | Buy |
| Dec 15, 2021 | BTIG | UPGRADE | Neutral | Buy |
| Oct 20, 2021 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Oct 19, 2021 | BTIG | DOWNGRADE | Buy | Neutral |
| Dec 16, 2020 | Credit Suisse | UPGRADE | Neutral | Outperform |
| Dec 7, 2020 | HC Wainwright & Co. | INITIATE | — | Buy |
| Nov 11, 2020 | Credit Suisse | MAINTAIN | — | Neutral |
| Jul 29, 2020 | Credit Suisse | MAINTAIN | — | Neutral |
| Dec 2, 2019 | BTIG | INITIATE | — | Buy |
| Dec 2, 2019 | B of A Securities | INITIATE | — | Buy |
| Dec 2, 2019 | Citigroup | INITIATE | — | Buy |
| Dec 2, 2019 | Credit Suisse | INITIATE | — | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Mar 1, 2024 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Feb 1, 2024 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Jan 1, 2024 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Dec 1, 2023 | 0 | 0 | 4 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 13, 2026
earnings_calendar
GRTX Q1 2026 Earnings Scheduled — 2026-05-13
Apr 14, 2026
m_and_a
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
<p align="justify">CAMBRIDGE, Mass. and MALVERN, Pa., April 14, 2026 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (“Galera”) (OTC: GRTX), a clinica
Mar 30, 2026
earnings_calendar
GRTX Q4 2025 Earnings After Market Close — 2026-03-30